Therapeutic use of imidazole-5-carboxylic acid derivatives
The invention discloses the use of 2-butyl-4-chloro-1-[2′-(1H-tetrazol-5-yl)1,1′-biphenyl-methyl]-imidazole-5-carboxylic acid, 1-[(isopropoxycarbonyl)oxy] methyl ester and the pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of the damage of a target organ caused by hypertension. It particularly discloses the use of this compound in the manufacture of a medicament for the treatment of left ventricular hypertrophy, renal dysfunction, aorta thickening caused by hypertension, which provides an effective drug and method for the treatment of the damage of target organs for hypertension patients.
1. A method for the treatment of the damage of a target organ caused by hypertension, comprising administering to a subject in need thereof a compound of formula (I) or a pharmaceutically acceptable salt thereof
2. The method according to claim 1 , wherein the compound of formula (I) or the pharmaceutically acceptable salt thereof is administered in the dosage of about 0.1-about 50 mg/kg/day.
3. The method according to claim 1 , wherein the compound of formula (I) or the pharmaceutically acceptable salt thereof is administered in the dosage of about 0.5-about 20 mg/kg/day.
4. The method according to claim 1 , wherein said damage of a target organ comprises the damage of heart, brain, kidney or blood vessel caused by hypertension.
5. The method according to claim 4 , wherein said damage of a target organ comprises left ventricular hypertrophy, stroke, renal cortex atrophy or aorta thickening.
6. The method according to claim 1 , wherein the compound of formula (I) or the pharmaceutically acceptable salt thereof is formulated in a medicament, wherein said medicament comprises about 20 mg-1000 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
7. The method according to claim 1 , wherein the compound of formula (I) or the pharmaceutically acceptable salt thereof is formulated in a medicament, wherein said medicament comprises about 50-about 500 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
8. The method according to claim 1 , wherein the dosage form of said medicament is an oral dosage form, injection, formulation for sublingual administration, or patch, preferably comprises tablet, capsule, granule, pill, or suspension.
9. A method for the treatment of the damage of a target organ caused by hypertension, comprising administering to a subject in need thereof a composition comprising the compound of formula (I) or a pharmaceutically acceptable salt thereof
10. The method according to claim 9 , wherein the content of the compound of formula (I) or the pharmaceutically acceptable salt thereof in the composition is about 20 mg-about 1000 mg.
11. A pharmaceutical composition for oral or sublingual administration, which contains about 50 mg-about 1000 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier
12. The pharmaceutical composition according to the claim 11 , wherein the content of the compound of formula (I) or the pharmaceutically acceptable salt thereof in said composition is about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg or about 1000 mg.